Day One Biopharmaceuticals shares are trading higher after B of A Securities upgraded the stock from Underperform to Buy and raised its price target from $11 to $24.
Portfolio Pulse from Benzinga Newsdesk
Day One Biopharmaceuticals shares are trading higher after B of A Securities upgraded the stock from Underperform to Buy and raised its price target from $11 to $24.
August 01, 2024 | 11:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Day One Biopharmaceuticals shares are trading higher after B of A Securities upgraded the stock from Underperform to Buy and raised its price target from $11 to $24.
The upgrade from Underperform to Buy by a major financial institution like B of A Securities, along with a significant increase in the price target, is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100